about
Modelling and simulation as research tools in paediatric drug developmentTesting new drugs in naked apes and getting the dose right in their youngFirst dose in neonates: are juvenile mice, adults and in vitro-in silico data predictive of neonatal pharmacokinetics of fluconazole.Assessment of the Absorbed Dose in the Kidney of Nuclear Nephrology Paediatric Patients using ICRP Biokinetic Data and Monte Carlo Simulations with Mass-Scaled Paediatric Voxel Phantoms.Interspecies allometric scaling of antimalarial drugs and potential application to pediatric dosing.Bridging the gap: a review of dose investigations in paediatric investigation plansDosage considerations for transcranial direct current stimulation in children: a computational modeling study.Improving antibiotic prescribing for children in the resource-poor setting.Paediatric drug development: are population models predictive of pharmacokinetics across paediatric populations?Predicting pediatric age-matched weight and body mass indexScaling adult doses of antifungal and antibacterial agents to childrenEffect of Kidney Function on Drug Kinetics and Dosing in Neonates, Infants, and ChildrenScaling of pharmacokinetics across paediatric populations: the lack of interpolative power of allometric models.Effect of reducing the paediatric stavudine dose by half: a physiologically-based pharmacokinetic model.Simultaneous pharmacokinetic modeling of gentamicin, tobramycin and vancomycin clearance from neonates to adults: towards a semi-physiological function for maturation in glomerular filtrationAdaptive trials in paediatric development: dealing with heterogeneity and uncertainty in pharmacokinetic differences in children.Population pharmacokinetics of abacavir in infants, toddlers and children.The influence of CYP2C8*3 on carbamazepine serum concentration in epileptic pediatric patients.The allometric exponent for scaling clearance varies with age: a study on seven propofol datasets ranging from preterm neonates to adults.Covariate effects and population pharmacokinetics of lamivudine in HIV-infected children.Modeling and simulation in pediatric drug therapy: Application of pharmacometrics to define the right dose for children.Personalised dosing of medicines for children.Adaptive dosing of anticancer drugs in neonates: facilitating evidence-based dosing regimens.How to optimise drug study design: pharmacokinetics and pharmacodynamics studies introduced to paediatricians.Impact of disease, drug and patient adherence on the effectiveness of antiviral therapy in pediatric HIV.The effects of Cognitive Bias Modification training and oxytocin administration on trust in maternal support: study protocol for a randomized controlled trial.Dosing rationale for fixed-dose combinations in children: shooting from the hip?Bottom-up Meets Top-down: Complementary Physiologically Based Pharmacokinetic and Population Pharmacokinetic Modeling for Regulatory Approval of a Dosing Algorithm of Valganciclovir in Very Young Children.Bridging strategies for drug combinations in pediatric indications.Quantitation of salbutamol using micro-volume blood sampling - applications to exacerbations of pediatric asthma.Evidence-Based Design of Fixed-Dose Combinations: Principles and Application to Pediatric Anti-Tuberculosis Therapy.Residual volume in vials of antibiotics used in pediatrics.Inconsistencies in dosage practice in children with overweight or obesity: A retrospective cohort study.Higher chlorzoxazone clearance in obese children compared with nonobese peersPost hoc analyses of asenapine treatment in pediatric patients with bipolar I disorder: efficacy related to mixed or manic episode, stage of illness, and body weight
P2860
Q27010366-5F32BCBC-EA89-4B74-A888-6A791BAB8D20Q28748959-688C1CDB-5397-4821-8BC6-3F2AF3F1EC98Q30844731-412685F3-E499-4FF8-ACC5-0F218A9D2CB1Q31082910-01F02B28-2BAE-4E39-8F59-68145C96D8FAQ34299078-2F4B685E-77B6-450A-A9B6-88E0813878A2Q34554486-F3F1A2F5-1E4B-4CDB-BA0A-7D153CB40446Q35006209-F2DC31D0-97C3-4448-A0DF-7680D29350C5Q35135959-16159B5E-56A1-4652-B604-60CA07240327Q35219662-0816078E-A22C-4409-8BF9-3A00223FE6A8Q35318223-161BD135-215A-4DA0-9197-CFF02F9A3AC4Q36018577-6209786E-6C41-4541-A3AA-90C0CCDD7296Q36322918-957B8C58-6776-4B86-8758-FF6333C3AD9BQ36336064-4F56A9D0-C544-4B43-8025-33203B13D574Q36558893-E4E96CEC-7E91-4AF9-BB0D-1EA119480669Q36568925-C5395BA9-0454-4FAD-BADC-01CD396CCC47Q36779152-F081BDFE-D2CC-4DA5-A2C3-C71D7FE2D3E1Q36948138-91E0D1D3-56C5-4A6E-B573-94998C666CE7Q37262064-A65B1D11-A9DD-4558-B73E-1CFE56B84FC1Q37492046-C8804856-93FA-4345-B69E-54001424D9E8Q37731863-72DC266B-20DE-4E9A-813C-C5F893E14004Q38527434-68E5BE47-8C89-4F0F-99BC-34E0DFB7FB8EQ38749764-84D8F05E-0260-414E-8A1E-6027A14D30EBQ38908387-F0F6F1DC-210F-4F8E-94A1-2B9026EC31B7Q38965300-3CA232B7-7387-40B4-96AB-57344DB24E82Q39064765-4862A8B8-D9FA-46DF-9686-27BFD2B4FBB0Q41032529-0FD33D42-D701-419E-99F2-F6289B9E6F9AQ44677507-5085A993-2EC0-40B4-B4DB-612C1666724CQ44781273-CF3DB151-FD30-4FA9-A192-6DEFAB0A667FQ45841885-F7789240-B455-44B1-8FD5-35D6BEF69482Q47688683-BC92DFE2-94F4-4449-B83E-BF10CA8C518AQ48287062-479310EE-DC83-40E2-A42E-0FA4BD0F36D8Q50585024-F8953B80-4259-4AF7-8DC6-0102A784914BQ55417154-3489728D-8295-43F5-B7B1-AD47614D8B71Q56832197-48C2E537-6BED-47E5-9A91-32FF17150484Q58803511-5A5AEC21-6072-499B-9A71-4D9C197D748C
P2860
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
What is the right dose for children?
@ast
What is the right dose for children?
@en
What is the right dose for children?
@nl
type
label
What is the right dose for children?
@ast
What is the right dose for children?
@en
What is the right dose for children?
@nl
prefLabel
What is the right dose for children?
@ast
What is the right dose for children?
@en
What is the right dose for children?
@nl
P2093
P2860
P1476
What is the right dose for children?
@en
P2093
Catherijne Knibbe
Massimo Cella
Meindert Danhof
Oscar Della Pasqua
P2860
P304
P356
10.1111/J.1365-2125.2009.03591.X
P407
P577
2010-10-01T00:00:00Z